Walerych Dawid, Pruszko Magdalena, Zyla Lukasz, Wezyk Michalina, Gaweda-Walerych Katarzyna, Zylicz Alicja
Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.
International Institute of Molecular and Cell Biology in Warsaw, 02-109 Warsaw, Poland.
Oncotarget. 2018 Aug 10;9(62):32063-32080. doi: 10.18632/oncotarget.25944.
Human p53 protein acts as a transcription factor predominantly in a tetrameric form. Single residue changes, caused by hot-spot mutations of the gene in human cancer, transform wild-type (wt) p53 tumor suppressor proteins into potent oncoproteins - with gain-of-function, tumor-promoting activity. Oligomerization of p53 allows for a direct interplay between wt and mutant p53 proteins if both are present in the same cells - where a mutant p53's dominant-negative effect known to inactivate wt p53, co-exists with an opposite mechanism - a "dominant-positive" suppression of the mutant p53's gain-of-function activity by wt p53. In this study we determine the oligomerization efficiency of wt and mutant p53 in living cells using FRET-based assays and describe wt p53 to be more efficient than mutant p53 in entering p53 oligomers. The biased p53 oligomerization helps to interpret earlier reports of a low efficiency of the wt p53 inactivation via the dominant-negative effect, while it also implies that the "dominant-positive" effect may be more pronounced. Indeed, we show that at similar wt:mutant p53 concentrations in cells - the mutant p53 gain-of-function stimulation of gene transcription and cell migration is more efficiently inhibited than the wt p53's tumor-suppressive transactivation and suppression of cell migration. These results suggest that the frequent mutant p53 accumulation in human tumor cells does not only directly strengthen its gain-of-function activity, but also protects the oncogenic p53 mutants from the functional dominance of wt p53.
人类p53蛋白主要以四聚体形式发挥转录因子的作用。人类癌症中该基因的热点突变导致的单个残基变化,将野生型(wt)p53肿瘤抑制蛋白转变为具有功能获得性、促肿瘤活性的强效癌蛋白。如果野生型和突变型p53蛋白同时存在于同一细胞中,p53的寡聚化会使它们之间产生直接相互作用——已知突变型p53的显性负效应会使野生型p53失活,同时存在一种相反的机制——野生型p53对突变型p53功能获得性活性的“显性正”抑制。在本研究中,我们使用基于荧光共振能量转移(FRET)的检测方法测定了野生型和突变型p53在活细胞中的寡聚化效率,并描述野生型p53比突变型p53更有效地进入p53寡聚体。有偏向性的p53寡聚化有助于解释早期关于通过显性负效应使野生型p53失活效率较低的报道,同时也意味着“显性正”效应可能更明显。实际上,我们表明在细胞中野生型与突变型p53浓度相似时,与野生型p53的肿瘤抑制性反式激活和细胞迁移抑制相比,突变型p53功能获得性对基因转录和细胞迁移的刺激受到更有效的抑制。这些结果表明,人类肿瘤细胞中频繁积累的突变型p53不仅直接增强了其功能获得性活性,还保护致癌性p53突变体免受野生型p53的功能主导。